Du, L., Li, C., & Lei, J. (2026). Quantitative cancer-immunity cycle modeling to optimize bevacizumab and atezolizumab combination therapy for advanced renal cell carcinoma.
Style de citation Chicago (17e éd.)Du, Lei, Chenghang Li, et Jinzhi Lei. Quantitative Cancer-immunity Cycle Modeling to Optimize Bevacizumab and Atezolizumab Combination Therapy for Advanced Renal Cell Carcinoma. 2026.
Style de citation MLA (9e éd.)Du, Lei, et al. Quantitative Cancer-immunity Cycle Modeling to Optimize Bevacizumab and Atezolizumab Combination Therapy for Advanced Renal Cell Carcinoma. 2026.
Attention : ces citations peuvent ne pas être correctes à 100%.